Documents
Médias
KalVista Pharmaceuticals Wins £2.4m Biomedical Catalyst Grant to Further Develop Oral Plasma Kallikrein Inhibitors as a Treatment for Diabetic Macular Edema
Editeur
KalVista-Pharmaceuticals
Publications
(
1
)